Trial Profile

Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 17 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favipiravir (Primary) ; Interferon alpha-1b; Lopinavir/ritonavir
Indications COVID 2019 infections; Pneumonia
Focus Therapeutic Use

Most Recent Events

16 May 2020 New source identified and integrated (Chinese Clinical Trial Register ChiCTR2000029600).
24 Mar 2020 New trial record
19 Mar 2020 According to an Zhejiang Hisun Pharmaceutical Media Release, preliminary results of this study were released at a press conference held by the Ministry of Science and Technology of the P.R.C.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com